

Issues raised by DOL in Document "Part B Lung Diseases"  
Presented at April 2016 meeting

**Beryllium sensitization / BeLPT / medical monitoring**

1. Sensitivity: Consistency of testing results amongst different diagnostic facilities
2. Sensitivity: Reinterpretation by "normal" test outcomes as abnormal by a consulting physician
3. New and more relevant science on diagnostic tools for evaluating beryllium sensitivity
4. Definition of beryllium medical monitoring i.e. expected medical regimen for monitoring sensitivity to determine if it has progressed to CBD

**Diagnostic Criteria CBD** (including onset disease pre / post 1993)

5. Clarification of the diagnostic and interpretive meaning of "characteristic of CBD" to differentiate between CBD and other lung disease
6. Consistent and uniform standard for judging medical evidence for the pre or post 1993 as evidence of a "chronic respiratory disorder"
8. Obtaining clarity on the specific diagnostic markers required for CBD in the pre or post 1993 diagnostic requirements

**Complications Disease & Treatment / Impact treatment and disease on diagnosis**

7. Necessitating lung lavages or lung biopsy on critically ill or elderly patients
10. Recommendations or advice relating to conditions that are normal and usual consequential illnesses to CBD
11. Input regarding assessment of negative BeLPT as either false-negative or borderline due to drug interference or other treatment modalities

**Sarcoidosis**

9. Guidance on the relationship between sarcoidosis and CBD

**Silicosis:**

12. Guidance on the certification requirements for B-readers and how that is documented on B-reader test results

.